US Edition
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
Nicox SA announced the completion of patient treatment and follow-up in the Denali phase 3 clinical trial for NCX 470, its lead candidate for the treatment of open-angle glaucoma and ocular hypertension. In total, 696 patients were enrolled across the United States and China. Topline results from the trial are expected between mid-August and mid-September 2025. “Reaching the milestone of the last patient last visit in the Denali phase 3 trial is…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
